ArticleFrontiers in oncology2023

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report.

Zhifeng Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.